Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)

Research output: Contribution to journalArticleAcademicpeer-review

48 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)586-595
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume103
Issue number2
DOIs
Publication statusPublished - 2018

Cite this